• Positive RNAi results Silences critics

    September 21, 2017 | Posted by

    By Richard Gill, CFA It’s good news for the RNA interference industry as US listed market leader Alnylam Pharmaceuticals (NASDAQ:ALNY) announced positive results this week from its Phase 3 study of nerve disorder drug patisiran. This is a very positive development for an industry which has promised much but seen numerous challenges over the past few […]

  • Align Research Recommendations update

    September 3, 2017 | Posted by

    As equity markets globally continue to push on in the face of historically extreme valuations whilst seemingly ignoring recession risk in the US and increasing geo-political tensions, we believe that caution is very much warranted now and indeed it is time to actively raise cash and take advantage of the distribution opportunities that the buoyant […]

  • Open Letter to Pat Plunkett of Providence Resources

    September 1, 2017 | Posted by

    Dear Mr Plunkett You will be familiar with my prior missives in regards to the direction of Providence Resources under the stewardship of Tony O’Reilly Jnr. If you have not taken the time to read them, here is the link for you – http://www.alignresearch.co.uk/category/providence-resources/ Stark fact number 1 – as of today’s date (1 Sep […]